Wednesday, 29 October 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 29 October 2025
News

CSL's Seqirus spin-off on pause

Posted 28 October 2025 PM

CSL has indefinitely delayed the spin-off of Seqirus, as its share price plummeted on Tuesday due to the local giant slashing its growth forecast.

The reason given for the delay in separating Seqirus was higher than expected declines in vaccination rates in the US, likely due to US Health Secretary Robert Kennedy Jr's attacks on the technology. While he has focused on removing thimersol from vaccines because antivax groups claim, without evidence, that it causes autism, a portion of the general public doesn't recognise that distinction and has reduced trust in all vaccines.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (3)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.